STOCK TITAN
  1. Home
  2. Sec-filings
  3. IOVA
  4. [Form 4] IOVANCE BIOTHERAPEUTICS, INC. Insider Trading Activity

Iovance CRO has 5,470 RSUs vest into shares

Chief Regulatory Officer Raj K. Puri reported RSU vesting at IOVA, with a portion of shares withheld to cover tax obligations.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Chief Regulatory Officer Raj K. Puri had 5,470 Restricted Stock Units (RSUs) vest on September 1, 2026, each converting into one share of common stock. Of these, 2,508 shares of common stock were withheld by the company at $8.28 per share to satisfy mandatory tax withholding requirements, which is explicitly stated not to be an open market sale. Following this vesting event, 10,939 RSUs remain outstanding from the March 1, 2024 grant, in addition to any other RSUs he holds under separate awards.

Positive

  • None.

Negative

  • None.
Insider Puri Raj K.
Role Chief Regulatory Officer
Type Security Shares Price Value
Exercise Restricted Stock Units F4, F5, F6 5,470 $0.00 $0.00
Exercise Common Stock F1 5,470 $0.00 $0.00
Tax Withholding Common Stock F2, F3 2,508 $8.28 $21K
Holdings After Transaction: Restricted Stock Units — 10,939 contracts (Direct); Common Stock — 251,076 shares (Direct)
Footnotes (6)
  1. F1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
  2. F2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
  3. F3. Represents the common stock remaining after deducting the common stock withheld for taxes.
  4. F4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
  5. F5. The remaining RSUs will vest in equal quarterly installments.
  6. F6. Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.
RSUs vested 5,470 units Restricted Stock Units vested and converted into common stock on September 1, 2026
Shares withheld for taxes 2,508 shares Common stock withheld to satisfy mandatory tax withholding on RSU vesting
Withholding price $8.28 per share Value used for the 2,508 shares withheld for tax obligations
RSUs remaining from March 1, 2024 grant 10,939 units Aggregate number of unvested RSUs remaining from the March 1, 2024 award after this vesting
RSU-to-share ratio 1 RSU : 1 share Each RSU represents a contingent right to receive one share of common stock
Restricted Stock Units financial
"Represents such shares underlying the restricted stock units ("RSUs") which vested"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
mandatory tax withholding financial
"to satisfy the mandatory tax withholding requirements upon vesting of the RSUs"
contingent right financial
"Each RSU represents a contingent right to receive one share"
equal quarterly installments financial
"The remaining RSUs will vest in equal quarterly installments"

FAQ

What equity transaction did IOVA executive Raj K. Puri report on this Form 4?
Raj K. Puri reported the vesting of 5,470 RSUs on September 1, 2026, which converted into an equal number of IOVANCE BIOTHERAPEUTICS, INC. common shares, with some of those shares then withheld to cover tax withholding obligations.

How many IOVA RSUs vested for Raj K. Puri and into what did they convert?
On September 1, 2026, 5,470 RSUs held by Raj K. Puri vested. Each RSU represents a contingent right to receive one share of IOVANCE common stock, so the vesting resulted in 5,470 shares of common stock being issued in connection with this award.

How many IOVA shares were withheld for taxes in Raj K. Puri’s Form 4 filing?
The company withheld 2,508 shares of common stock from Raj K. Puri at a price of $8.28 per share to satisfy mandatory tax withholding requirements upon RSU vesting. The filing specifies that this was not an open market sale of securities.

How many RSUs from the March 1, 2024 IOVA grant remain for Raj K. Puri?
After the September 1, 2026 vesting, 10,939 RSUs remain from the grant made on March 1, 2024. The filing notes that these remaining RSUs will vest in equal quarterly installments and that other RSU awards held by him are not included in this figure.

Was Raj K. Puri’s IOVA Form 4 transaction under a Rule 10b5-1 trading plan?
The filing indicates that the Rule 10b5-1 checkbox is not affirmed, and the footnotes describe the activity as RSU vesting and related tax withholding. There is no disclosure that these transactions were effected under a Rule 10b5-1 trading plan.

What type of ownership does Raj K. Puri report for these IOVA securities?
For all reported securities in this Form 4, the ownership type is listed as direct. The filing does not attribute these holdings to any trust, LLC, or other indirect ownership vehicle, and there is no disclaimer of beneficial ownership for the reported positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Puri Raj K.
(Last)(First)(Middle)
C/O IOVANCE BIOTHERAPEUTICS, INC.
825 INDUSTRIAL ROAD, SUITE 100
(Street)
SAN CARLOS CALIFORNIA 94070
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Regulatory Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)09/01/2026M5,470A$0253,584D
Common Stock(2)09/01/2026F2,508D$8.28251,076(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(4)09/01/2026M5,470 (5) (5)Common stock5,470$0.0010,939(6)D
Explanation of Responses:
1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
3. Represents the common stock remaining after deducting the common stock withheld for taxes.
4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
5. The remaining RSUs will vest in equal quarterly installments.
6. Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.
/s/ Raj K. Puri09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR